Melanoma March 2016 is launched
2 February 2016
Melanoma Institute Australia (MIA) officially launched the 2016 ‘Melanoma March’ initiative in Sydney today.
The launch event held at the Sofitel Sydney Wentworth revealed plans for the new project that will receive funds from this year's Melanoma March campaign. Channel 7's Dr. Andrew Rochford hosted the event, with MIA"s new CEO Carole Renouf helping to get the campaign off to a flying start. Melanoma patient and author of Dear Melanoma Emma Betts also spoke passionately about the importance of research.
Professor Graham Mann, Research Director at MIA, explained how the Melanoma March campaign provides critical funding for an ambitious new project that will ultimately transform the way patients are treated by shining a research light on melanoma care.
Participating melanoma centres around the country will link databases, for the first time bringing together the key information about the treatment of their patients on a national scale. At present melanoma is only recorded by national cancer registries at the time it is initially diagnosed. Data suitable for research about the patients’ treatment and progress is currently only collected in a few specialist centres. This project seeks to expand this substantially and facilitate the appropriate combination of this invaluable information to provided new insights into treatment responses, especially with the less common forms of melanoma where our aggregated national experience will be so informative.
The world-leading ‘Big Data for Melanoma’ project will feature an online platform designed to engage with melanoma care, wherever it takes place.
“With melanoma cases still rising, it’s critical we find ways to keep improving the quality of care. Part of this challenge is to understand the real-world situation of melanoma across the country. This sort of clinical research register has not been attempted before in melanoma. It’s ultimately about improving patient care and saving lives,” MIA’s Research Director Professor Graham Mann said.
During the launch, MIA also updated progress on world-first research into treatment for melanoma brain metastases funded by money raised during the 2014 Melanoma March.
The ground-breaking ‘ABC Trial’, supported by Australia and New Zealand Melanoma Trials Group (ANZMTG), is comparing the use of various immunotherapies in patients with melanoma that has spread to their brain. Running since 2014, the study is showing promising early findings. Patients who once were given just months to live are now surviving longer than a year.
“It’s only early days, but so far we are seeing a tripling of life expectancy for some patients with melanoma that has spread to the brain. There are also added benefits because this kind of work is a world first. Everything we are using is unique – we’re developing new techniques to investigate and learn from the patients’ blood and tumour samples, together with much more advanced brain imaging, which is allowing us to stay at the forefront of research," MIA's Deputy Director Associate Professor Jonathan Stretch said.
Melanoma March events will be hosted in these 24 locations nationally from February 27–April 10, 2016:
QLD: Bribie Island, Brisbane, Cairns, Coolangatta, Townsville
SA: Adelaide, Port Lincoln
WA: Bunbury, Karratha, Perth CBD, Rockingham
NSW: Bathurst, Bonny Hills, Forster Tuncurry, Gosford, Manly, Picton, Wagga Wagga, Western Sydney, Wollongong
For more information about Melanoma March please visit: www.melanomamarch.org.au.
Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.
Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.
Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.